Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Korosho Study Group Issues GL on Terminal Care
April 30, 2007
-
ARCHIVE Generic Substitution Rate Remains "very Low" Despite New Prescription Form: Chuikyo
April 30, 2007
-
ARCHIVE Doctors' Average Monthly Salaries Up to \761,000
April 30, 2007
-
ARCHIVE Information on Incidence of ADRs Is Not Intellectual Property: PMDA's Mr Kishida
April 30, 2007
-
ARCHIVE Status of 5 Major Diseases in 2015 Surveyed: JHSF
April 30, 2007
-
ARCHIVE 29 New Drugs Approved
April 30, 2007
-
ARCHIVE Plavix to Drive Sales of sanofi-aventis in 2007: Mr Fauchet
April 30, 2007
-
ARCHIVE Shionogi to Hire More MRs to Promote Crestor, Irbesartan
April 23, 2007
-
ARCHIVE Medical Spending Should Be Increased: JMA President
April 23, 2007
-
ARCHIVE Asahi Kasei to Focus on 3 Fields
April 23, 2007
-
ARCHIVE Strict Control of cholesterol Required in Hyperlipidemia Patients with Diabetes
April 23, 2007
-
ARCHIVE Explosion at Shin-Etsu Chemical Affects Supply of Cellulose Derivatives
April 23, 2007
-
ARCHIVE Early Treatment of Hepatitis C Needed to Prevent Liver Cancer
April 23, 2007
-
ARCHIVE System That Reduces Number of Quick Deliveries Needed: Mr Choufuku of Mediceo Paltac
April 23, 2007
-
ARCHIVE TOPICS/NOXAFIL Recommended for Antifungal Prophylaxis: Schering-Plough
April 23, 2007
-
ARCHIVE Korosho to Hear Wholesalers, Hospitals, Pharmacies Again Over Agreements on Prices
April 23, 2007
-
ARCHIVE Bayer Yakuhin to Integrate Nihon Schering in July: Dr Portoff
April 23, 2007
-
ARCHIVE BUSINESS NEWS IN BRIEF
April 23, 2007
-
ARCHIVE 27th General Assembly of the Japan Medical Congress
April 23, 2007
-
ARCHIVE Japan, China, South Korea to Cooperate in Healthcare, Drug Development
April 23, 2007
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…